{"id":"l606","safety":{"commonSideEffects":[{"rate":null,"effect":"Cough"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Throat irritation"},{"rate":null,"effect":"Flushing"}]},"_chembl":{"chemblId":"CHEMBL1237119","moleculeType":"Small molecule","molecularWeight":"390.52"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"L606 uses Liquidia's PRINT technology to create uniform, engineered particles of treprostinil that can be inhaled as a dry powder. Treprostinil is a prostacyclin analog that acts as a vasodilator and antiplatelet agent, reducing pulmonary vascular resistance and improving hemodynamics in pulmonary hypertension patients. The dry powder inhalation route provides direct lung delivery with potentially improved bioavailability and patient convenience compared to parenteral formulations.","oneSentence":"L606 is an inhaled dry powder formulation of treprostinil designed to deliver the prostacyclin analog directly to the lungs for pulmonary hypertension treatment.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:18:03.605Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pulmonary arterial hypertension (PAH)"}]},"trialDetails":[{"nctId":"NCT04691154","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Liquidia Technologies, Inc.","startDate":"2021-08-01","conditions":"Pulmonary Arterial Hypertension, Pulmonary Hypertension Due to Lung Diseases","enrollment":28},{"nctId":"NCT07285655","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD","status":"NOT_YET_RECRUITING","sponsor":"Liquidia Technologies, Inc.","startDate":"2026-04","conditions":"Pulmonary Hypertension Due to Lung Disease (Disorder)","enrollment":344},{"nctId":"NCT04041648","phase":"PHASE1","title":"Single Ascending Dose Study for Evaluation of Safety, Tolerability and Pharmacokinetics of L606","status":"COMPLETED","sponsor":"Pharmosa Biopharm Inc.","startDate":"2018-11-09","conditions":"Pulmonary Arterial Hypertension","enrollment":52}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Treprostinil Liposome Inhalation Suspension"],"phase":"phase_3","status":"active","brandName":"L606","genericName":"L606","companyName":"Liquidia Technologies, Inc.","companyId":"liquidia-technologies-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"L606 is an inhaled dry powder formulation of treprostinil designed to deliver the prostacyclin analog directly to the lungs for pulmonary hypertension treatment. Used for Pulmonary arterial hypertension (PAH).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}